<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Res Notes</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Res Notes</journal-id>
      <journal-title-group>
        <journal-title>BMC Research Notes</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1756-0500</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25885670</article-id>
      <article-id pub-id-type="pmc">4403845</article-id>
      <article-id pub-id-type="publisher-id">1065</article-id>
      <article-id pub-id-type="doi">10.1186/s13104-015-1065-4</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Familial partial lipodystrophy, Dunnigan variety - challenges for patient care during pregnancy: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Belo</surname>
            <given-names>Sandra Patr&#xED;cia Mota</given-names>
          </name>
          <address>
            <email>sandra.belo@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Magalh&#xE3;es</surname>
            <given-names>&#xC2;ngela Celeste</given-names>
          </name>
          <address>
            <email>acfmagalhaes@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Freitas</surname>
            <given-names>Paula</given-names>
          </name>
          <address>
            <email>paula_freitas@sapo.pt</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Davide Maur&#xED;cio</given-names>
          </name>
          <address>
            <email>davideccarvalho@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Endocrinology, Diabetes and Metabolism of the Centro Hospitalar de S&#xE3;o Jo&#xE3;o, Porto, Portugal </aff>
        <aff id="Aff2"><label/>Faculty of Medicine of the University of Porto, Porto, Portugal </aff>
        <aff id="Aff3"><label/>Instituto de Investiga&#xE7;&#xE3;o e Inova&#xE7;&#xE3;o em Sa&#xFA;de, Universidade do Porto, Porto, Portugal </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>4</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>11</day>
        <month>4</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>8</volume>
      <elocation-id>140</elocation-id>
      <history>
        <date date-type="received">
          <day>1</day>
          <month>2</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>3</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Belo et al.; licensee BioMed Central. 2015</copyright-statement>
        <license license-type="open-access">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Familial partial lipodystrophy, Dunnigan variety, is a recognised autosomal dominant disorder which is caused by heterozygous missense mutations in the lamin A/C gene. Dunnigan lipodystrophy is characterised by a variable loss of fat from the extremities and trunk, as well as an excess of subcutaneous fat in the chin and supraclavicular area. The associated metabolic abnormalities include: insulin resistance, diabetes, dyslipidaemia and low leptin levels.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>The authors studied the case of a 24-year-old caucasian pregnant woman, with a past medical history of acute pancreatitis, combined dyslipidaemia and diabetes mellitus. At 7&#xA0;weeks of pregnancy she was referred to the outpatient endocrinology and obstetrics clinic for diabetes care. A physical examination revealed that she presented a loss of fat from the extremities and trunk and also had an excess of subcutaneous fat in the chin. Triglyceride levels were persistently high, and glycaemic control was only achieved through the administration of high doses of insulin (1.8 U/Kg/day). Dunnigan lipodystrophy was suspected and thus a genetic study was requested, which revealed the presence of c.1444C&#x2009;&gt;&#x2009;T (p.Arg482Trp) heterozygote mutation in the lamin A/C gene.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>This case is used to illustrate the importance of being able to recognise the clinical signs of this rare lipodystrophic syndrome, which may cause potentially severe consequences, and also the difficulties in treating it during pregnancy.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Dunnigan lipodystrophy</kwd>
        <kwd>FPLD2</kwd>
        <kwd>Insulin resistance</kwd>
        <kwd>Dyslipidaemia</kwd>
        <kwd>Leptin</kwd>
        <kwd>Pregnancy</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Background</title>
      <p>Lipodystrophies constitute a rare, heterogeneous group of metabolic disorders, which affect adipose tissue distribution, characterised by varying degrees of body fat loss and, in some instances, an abnormal localised accumulation of subcutaneous fat [<xref ref-type="bibr" rid="CR1">1</xref>-<xref ref-type="bibr" rid="CR5">5</xref>]. These disorders can be divided into &#x2018;generalised&#x2019;, or &#x2018;partial&#x2019;, depending on the degree and pattern of fat loss. Moreover, the generalised and partial divisions can be further partitioned into inherited, or acquired, forms. Metabolic complications, such as hypoleptinemia, marked insulin resistance, diabetes mellitus, dyslipidaemia and hepatic steatosis, are all generally associated with this condition and their severity is related to the extent of fat loss [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR6">6</xref>].</p>
      <p>The main subtypes of inherited lipodystrophies are autosomal recessive generalised lipodystrophy, linked to mutations of either <italic>BSCL2</italic> or <italic>AGPAT2</italic> genes [<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref>], and autosomal dominant partial lipodystrophy, which is caused by mutations in the <italic>PPARG</italic> [<xref ref-type="bibr" rid="CR9">9</xref>-<xref ref-type="bibr" rid="CR11">11</xref>] or <italic>LMNA</italic> [<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref>] genes.</p>
      <p>The Dunnigan lipodystrophy variety, also known as familial partial lipodystrophy type 2 (FPLD2; OMIM151660), is a rare autosomal dominant disease, with an estimated prevalence of less than 1 in 10 million [<xref ref-type="bibr" rid="CR3">3</xref>], which is caused by mutations in the <italic>LMNA</italic> gene, which is located in chromosome 1q21-22, encoding the nuclear proteins lamin A and C [<xref ref-type="bibr" rid="CR12">12</xref>-<xref ref-type="bibr" rid="CR14">14</xref>]. Lamin A and C are members of the intermediate filament protein family, and are required for nuclear lamina formation [<xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref>]. The mutant gene products may disrupt interaction with chromatin or other nuclear lamina proteins, resulting in abnormal differentiation and the premature death of adipocytes [<xref ref-type="bibr" rid="CR17">17</xref>-<xref ref-type="bibr" rid="CR19">19</xref>]. Most mutations cluster in the carboxy-terminal immunoglobulin domain of lamin A/C [<xref ref-type="bibr" rid="CR3">3</xref>], and the majority of patients have heterozygous missense mutations, affecting codon 482 on exon 8 [<xref ref-type="bibr" rid="CR20">20</xref>-<xref ref-type="bibr" rid="CR25">25</xref>]. FPLD2 patients are born with normal fat distribution and after puberty they lose subcutaneous fat from their extremities, trunk and gluteal regions. Excess fat may be redistributed to the face, neck, back, labia majora and the abdominal cavity or abdominal organs, namely the liver, which accounts for the high prevalence of hepatic steatosis [<xref ref-type="bibr" rid="CR26">26</xref>-<xref ref-type="bibr" rid="CR28">28</xref>]. Skeletal muscle fibres in patients with FPLD2 display significant hypertrophy [<xref ref-type="bibr" rid="CR29">29</xref>]. These patients also experience a multitude of metabolic complications, including hyperlipidaemia, hypertriglyceridaemia and diabetes. FLPD2 women, in whom the disease is usually more severe [<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref>], are at high risk of having hyperandrogenism, infertility, gestational diabetes, obstetrical complications and they require extra gynaecological and obstetrical care [<xref ref-type="bibr" rid="CR32">32</xref>].</p>
      <p>The authors now move on to describe the case of a FPLD2 female patient who was diagnosed during pregnancy.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <sec id="Sec3">
        <title>Prior to pregnancy</title>
        <p>The 24-year-old caucasian female patient had a past medical history of acute pancreatitis, and experienced her first episode at the age of 20, which was complicated by superior mesenteric vein thrombosis. The second episode occurred at the age of 21. Combined dylipidemia was diagnosed in this context and was initially treated with a statin and fibrate, but without adequate control. Niacinic acid was added, with improved control. Diabetes, classified as secondary to pancreatitis, was later diagnosed at the age of 22, and was treated with insulin since the beginning of its discovery. The patient was subsequently referred to endocrinology appointments, where hypercortisolism was suspected, but excluded. She abandoned these appointments shortly after.</p>
        <p>Her gynaecological and obstetric history was irrelevant, and she had no previous history of menstrual abnormalities, hyperandrogenism, or infertility.</p>
      </sec>
      <sec id="Sec4">
        <title>During pregnancy</title>
        <p>At 7&#xA0;weeks of pregnancy, she was referred to the outpatient endocrinology and obstetrics clinic, in the context of her diabetes. A physical examination revealed that she presented loss of fat from the extremities and trunk (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>a; 1b), excess of subcutaneous fat in the chin, and apparent muscle hypertrophy (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). According to the patient, these features had been present since early adolescence. No other typical clinical features were observed during the physical examination, namely hirsutism or acanthosis nigricans. As previously noted, the therapy for diabetes was insulin, with an initial total dose of 106 U/day (1.8 U/Kg/day). The patient was also treated with heparin and salmon oil. Statin, niacinic acid and fenofibrate treatment had already been suspended at the time pregnancy was confirmed. She presented good glycaemic control (HbA1c 4.7%, without hypoglycaemia) and triglyceride levels of 1566&#xA0;mg/dL (reference value &lt;150&#xA0;mg/dL), and so was prescribed treatment with gemfibrozil 600&#xA0;mg, twice a day. Considering her past medical history, and the clinical and biochemical characteristics, Dunnigan lipodystrophy was suspected, and a genetic study for mutations of lamin A/C was requested. The presence of exon 8 c.1444C&#x2009;&gt;&#x2009;T (p.Arg482Trp) heterozygote mutation in the <italic>LMNA</italic> gene was revealed. No other genes were sequenced.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>a and b Loss of adipose tissue from the extremities and the trunk.</bold>
</p></caption><graphic xlink:href="13104_2015_1065_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Abnormal deposition of adipose tissue on the chin.</bold>
</p></caption><graphic xlink:href="13104_2015_1065_Fig2_HTML" id="MO2"/></fig></p>
        <p>At 12&#xA0;weeks of pregnancy, the patient was admitted to the emergency department with the diagnosis of acute pancreatitis, with triglyceride levels of 9975&#xA0;mg/dL. After improvement of triglyceride levels provoked by fasting, treatment began with fenofibrate 267&#xA0;mg, once a day, and the patient was discharged with triglyceride levels of 655&#xA0;mg/dL. One week later, on re-evaluation, she presented triglyceride levels of 2965&#xA0;mg/dL. Considering the risk of a new episode of pancreatitis, the patient was then admitted for metabolic control, centred on fasting. After discharge, with triglyceride levels of 1086&#xA0;mg/dL, a rigorous dietary plan was prescribed, and treatment was also started with Omacor&#xAE; [highly purified omega-3 fatty acid ethyl esters (3&#xA0;g tid)] and Protifar&#xAE; [high protein powdered supplement (32 sp)]. Triglyceride levels remained constantly between 1000 and 2000&#xA0;mg/dL until the birth. The birth was by dystocic delivery &#x2013; caesarean section - because of the failure of natural labour. The operation proceeded without complications and the new-born, although macrosomic (4675&#xA0;g), presented no clinical signs of having the disease, as was expected.</p>
      </sec>
      <sec id="Sec5">
        <title>After delivery</title>
        <p>After delivery, the patient begun regular evaluation during endocrinology appointments and returned to statin (rosuvastatin 20&#xA0;mg), cholestyramine (4000&#xA0;mg once a day) and fibrate (fenofibrate 267&#xA0;mg once a day) treatment, with suboptimal triglyceride levels control (triglyceride levels of 882&#xA0;mg/dL). For diabetes treatment, metformin was added to insulin, with good glycaemic control (HbA1c&#x2009;&lt;&#x2009;7%).</p>
      </sec>
      <sec id="Sec6">
        <title>Family history</title>
        <p>With regards to her family medical history, the patient has 3 healthy brothers and a healthy father. However her mother has type 2 diabetes <italic>mellitus</italic>, hypertriglyceridaemia and, according to the patient, she also has the same fat distribution pattern. No history of pancreatitis is known.</p>
        <p>Medical evaluation and a genetic study, if appropriate, was offered to all close relatives, but not one agreed to be studied (Figure&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Family pedigree.</bold>
</p></caption><graphic xlink:href="13104_2015_1065_Fig3_HTML" id="MO3"/></fig></p>
        <p>The new-born was referred for genetic appointments, in order to be studied for the presence of the mutation, but this has not been performed yet.</p>
      </sec>
    </sec>
    <sec id="Sec7" sec-type="discussion">
      <title>Discussion</title>
      <p>The present case illustrates the importance of early diagnosis of FPLD2, as well as the challenges faced by medical professionals when prescribing treatment for FPLD2 during gestation, especially considering the limitations imposed on treatment options during pregnancy.</p>
      <p>Our patient has demonstrated the typical Dunnigan-variety fat distribution since early adulthood. Before being pregnant, she also experienced two acute and severe episodes of pancreatitis, which were secondary to extremely high triglyceride levels. As occurs in some patients, she was erroneously suspected of having Cushing syndrome, but this hypothesis was excluded.</p>
      <p>Despite these clinical manifestations, FPLD2 was only diagnosed during pregnancy. The diagnosis was confirmed by a genetic study. Mutations of the codon 482 of the <italic>LMNA</italic> gene account for the majority of cases reported [<xref ref-type="bibr" rid="CR20">20</xref>-<xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR33">33</xref>-<xref ref-type="bibr" rid="CR35">35</xref>], and, although this residue is traditionally considered a mutational hot spot for FPLD2, other mutations in exon 8 (codon 465, 466, 485 and 486) and in exon 11 (codon 582, 583 and 584) have been recorded [<xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR36">36</xref>].</p>
      <p>Lack of fertility and obstetrical complications are frequent with FPLD2. Vantyghem <italic>et al.</italic> reported a prevalence of polycystic ovarian syndrome of more than 50%, of infertility close to 30%, miscarriages of 50%, gestational diabetes of at least 30%, and preeclampsia and foetal death of over 10% [<xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR32">32</xref>]. Contrary to these previous reports, our patient had no history of polycystic ovarian syndrome, nor any signs of hyperandrogenism, and presented no difficulties in conceiving.</p>
      <p>There is no specific treatment for FPLD2, and patients are prone to develop acute pancreatitis, long-term complications of diabetes, liver steatosis and cirrhosis, and also accelerated atherosclerosis.</p>
      <p>Currently, the insulin-sensitizing strategy uses lifestyle modifications (diet, physical activity) as a first line of approach. Metformin or glitazones add some benefit when lifestyle modifications alone are not sufficient. However, many patients do not achieve adequate glycaemic control with oral antidiabetic medications, and most require high insulin doses [<xref ref-type="bibr" rid="CR37">37</xref>-<xref ref-type="bibr" rid="CR39">39</xref>].</p>
      <p>Hypertriglyceridaemia is often resistant to conventional treatment. Fibric acid derivatives (PPAR&#x3B1; agonists) can be helpful, as well as high-dose omega&#x2009;&#x2212;&#x2009;3 polyunsaturated fatty acids. With some patients, low-dose statins, which also inhibit prelamin A farnesylation, can be added to reduce non-HDL-cholesterol levels [<xref ref-type="bibr" rid="CR37">37</xref>].</p>
      <p>Regarding adipocytokine replacement, the use of recombinant leptin in hypoleptinemic patients with lipodystrophies gives very promising results, with marked improvement in hyperglycaemia, hypertriglyceridemia, and hepatic steatosis [<xref ref-type="bibr" rid="CR40">40</xref>-<xref ref-type="bibr" rid="CR43">43</xref>]. Leptin therapy reduces appetite and causes weight loss, which contributes to reducing metabolic complications. In addition to its main effects, leptin also reduces ectopic lipid deposition in the liver and muscle [<xref ref-type="bibr" rid="CR44">44</xref>]. However, the effects of leptin are less significant in patients with partial lipodystrophies and other laminopathies, than in those with generalised lipodystrophies [<xref ref-type="bibr" rid="CR41">41</xref>]. In this context, the FDA has recently approved metreleptin (Myalept&#xAE;) treatment, but only for patients with generalised, inherited and acquired, lipodystrophies [<xref ref-type="bibr" rid="CR45">45</xref>]. This approval was based on results from an NIH open-label, single-arm study of 48 patients with congenital, or acquired generalized lipodystrophy, who also had diabetes <italic>mellitus</italic>, hypertriglyceridemia, and/or elevated levels of fasting insulin [<xref ref-type="bibr" rid="CR46">46</xref>].</p>
      <p>However, even though leptin replacement seems to be the ideal treatment for metabolic complications in FPLD2 patients, metreleptin is not yet commercially available for these patients. Metreleptin is a pregnancy category C treatment, so it should only be used if the forecast benefit justifies the potential risk for the foetus.</p>
      <p>At pregnancy conventional anti-dyslipidemic therapies &#x2013; such as statins, niacinic acid and some fibric acid derivates &#x2013; and some oral antidiabetic medications are contraindicated, or at least, not recommended. Adding to these limitations, normal pregnancy is characterised by a 2 to 4-fold increase in plasma triglyceride concentration, and also increased insulin resistance [<xref ref-type="bibr" rid="CR47">47</xref>]. These changes, which are well tolerated by most women with normal baseline triglyceride levels and no compromised metabolic pathways, do however constitute an increased risk of pancreatitis for women with FPLD2, mainly during a period of life when treatment options are limited.</p>
      <p>On account of the risk of pancreatitis, our patient was submitted to an alternative treatment, using highly purified omega-3 fatty acid ethyl esters [<xref ref-type="bibr" rid="CR48">48</xref>], and a high protein powdered supplement combined with fenofibrate, after discussion of the possible risks involved.</p>
    </sec>
    <sec id="Sec8" sec-type="conclusion">
      <title>Conclusion</title>
      <p>This case illustrates the importance of a timely diagnosis of FPLD2 in order to avoid severe, and possible life-threatening consequences, such as pancreatitis. The authors intend also to highlight the challenges involved when confronting this condition in pregnant women.</p>
    </sec>
    <sec id="Sec9">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>FPLD2</term>
          <def>
            <p>Familial partial lipodystrophy, Dunnigan variety</p>
          </def>
        </def-item>
        <def-item>
          <term>
            <italic>LMNA</italic>
          </term>
          <def>
            <p>Lamin A/C gene</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>SB drafted the manuscript and participated in the diagnosis and treatment of the patient. AM helped to draft the manuscript and also participated in the diagnosis and treatment of the patient, as did PF. DC helped to draft the manuscript. All the authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reitman</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Arioglu</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gavrilova</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>SI</given-names>
            </name>
          </person-group>
          <article-title>Lipoatrophy revisited</article-title>
          <source>Trends Endocrinol Metab</source>
          <year>2000</year>
          <volume>11</volume>
          <fpage>410</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1016/S1043-2760(00)00309-X</pub-id>
          <pub-id pub-id-type="pmid">11091118</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nolis</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies</article-title>
          <source>J Hum Genet</source>
          <year>2014</year>
          <volume>59</volume>
          <issue>1</issue>
          <fpage>16</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="doi">10.1038/jhg.2013.107</pub-id>
          <pub-id pub-id-type="pmid">24152769</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Acquired and inherited lipodystrophies</article-title>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>350</volume>
          <fpage>1220</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra025261</pub-id>
          <pub-id pub-id-type="pmid">15028826</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Agarwal</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <article-title>Lipodystrophies: disorders of adipose tissue biology</article-title>
          <source>Biochim Biophys Acta</source>
          <year>2009</year>
          <volume>1791</volume>
          <fpage>507</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbalip.2008.12.014</pub-id>
          <pub-id pub-id-type="pmid">19162222</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Misra</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Lipodystrophies: rare disorders causing metabolic syndrome</article-title>
          <source>Endocrinol Metab Clin North Am</source>
          <year>2004</year>
          <volume>33</volume>
          <fpage>305</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ecl.2004.03.003</pub-id>
          <pub-id pub-id-type="pmid">15158521</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agarwal</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Genetic basis of lipodystrophies and management of metabolic complications</article-title>
          <source>Annu Rev Med</source>
          <year>2006</year>
          <volume>57</volume>
          <fpage>297</fpage>
          <lpage>311</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev.med.57.022605.114424</pub-id>
          <pub-id pub-id-type="pmid">16409151</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Magre</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Delepine</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Khallouf</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gedde-Dahl</surname>
              <given-names>T</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Van Maldergem</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sobel</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13</article-title>
          <source>Nat Genet</source>
          <year>2001</year>
          <volume>28</volume>
          <fpage>365</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="doi">10.1038/ng585</pub-id>
          <pub-id pub-id-type="pmid">11479539</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agarwal</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Arioglu</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>De Almeida</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Akkoc</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>SI</given-names>
            </name>
            <name>
              <surname>Bowcock</surname>
              <given-names>AM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34</article-title>
          <source>Nat Genet</source>
          <year>2002</year>
          <volume>31</volume>
          <fpage>21</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="doi">10.1038/ng880</pub-id>
          <pub-id pub-id-type="pmid">11967537</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agarwal</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2002</year>
          <volume>87</volume>
          <fpage>408</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="pmid">11788685</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hegele</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Frankowski</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mathews</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Leff</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy</article-title>
          <source>Diabetes</source>
          <year>2002</year>
          <volume>51</volume>
          <fpage>3586</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="doi">10.2337/diabetes.51.12.3586</pub-id>
          <pub-id pub-id-type="pmid">12453919</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Savage</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Acerini</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Jebb</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Agostini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gurnell</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma</article-title>
          <source>Diabetes</source>
          <year>2003</year>
          <volume>52</volume>
          <fpage>910</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.2337/diabetes.52.4.910</pub-id>
          <pub-id pub-id-type="pmid">12663460</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cao</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hegele</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy</article-title>
          <source>Hum Mol Genet</source>
          <year>2000</year>
          <volume>9</volume>
          <fpage>109</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="doi">10.1093/hmg/9.1.109</pub-id>
          <pub-id pub-id-type="pmid">10587585</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shackleton</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lloyd</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Niermeijer</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>BM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>LMNA, encoding lamin A/C, is mutated in partial lipodystrophy</article-title>
          <source>Nat Genet</source>
          <year>2000</year>
          <volume>24</volume>
          <fpage>153</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1038/72807</pub-id>
          <pub-id pub-id-type="pmid">10655060</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hegele</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Hramiak</surname>
              <given-names>IM</given-names>
            </name>
          </person-group>
          <article-title>Heterogeneity of nuclear lamin A mutations in Dunnigan-type familial partial lipodystrophy</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2000</year>
          <volume>85</volume>
          <fpage>3431</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">10999845</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gruenbaum</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Margalit</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Goldman</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Shumaker</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>KL</given-names>
            </name>
          </person-group>
          <article-title>The nuclear lamina comes of age</article-title>
          <source>Nat Rev Mol Cell Biol</source>
          <year>2005</year>
          <volume>6</volume>
          <fpage>21</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="doi">10.1038/nrm1550</pub-id>
          <pub-id pub-id-type="pmid">15688064</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aebi</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Cohn</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Buhle</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gerace</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>The nuclear lamina is a meshwork of intermediate-type filaments</article-title>
          <source>Nature</source>
          <year>1986</year>
          <volume>323</volume>
          <fpage>560</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1038/323560a0</pub-id>
          <pub-id pub-id-type="pmid">3762708</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agarwal</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>RI</given-names>
            </name>
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Genetic basis of congenital generalized lipodystrophy</article-title>
          <source>Int J Obes Relat Metab Disord</source>
          <year>2004</year>
          <volume>28</volume>
          <fpage>336</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">14557833</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boguslavsky</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Worman</surname>
              <given-names>HJ</given-names>
            </name>
          </person-group>
          <article-title>Nuclear lamin A inhibits adipocyte differentiation: implications for Dunnigan-type familial partial lipodystrophy</article-title>
          <source>Hum Mol Genet</source>
          <year>2006</year>
          <volume>15</volume>
          <fpage>653</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="doi">10.1093/hmg/ddi480</pub-id>
          <pub-id pub-id-type="pmid">16415042</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caron</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Auclair</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Donadille</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bereziat</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Guerci</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Laville</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence</article-title>
          <source>Cell Death Differ</source>
          <year>2007</year>
          <volume>14</volume>
          <fpage>1759</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.cdd.4402197</pub-id>
          <pub-id pub-id-type="pmid">17612587</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haque</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Oral</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Dietz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bowcock</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Agarwal</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Risk factors for diabetes in familial partial lipodystrophy, Dunnigan variety</article-title>
          <source>Diabetes Care</source>
          <year>2003</year>
          <volume>26</volume>
          <fpage>1350</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.2337/diacare.26.5.1350</pub-id>
          <pub-id pub-id-type="pmid">12716787</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peters</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gitomer</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Bowcock</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22</article-title>
          <source>Nat Genet</source>
          <year>1998</year>
          <volume>18</volume>
          <fpage>292</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.1038/ng0398-292</pub-id>
          <pub-id pub-id-type="pmid">9500556</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Speckman</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Veile</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Arioglu</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C</article-title>
          <source>Am J Hum Genet</source>
          <year>2000</year>
          <volume>66</volume>
          <fpage>1192</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1086/302836</pub-id>
          <pub-id pub-id-type="pmid">10739751</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vinaitheerthan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Weatherall</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Bowcock</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Phenotypic heterogeneity in patients with familial partial lipodystrophy (dunnigan variety) related to the site of missense mutations in lamin a/c gene</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2001</year>
          <volume>86</volume>
          <fpage>59</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="pmid">11231979</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Savage</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Soos</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Powlson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>O&#x2019;Rahilly</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>McFarlane</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Halsall</surname>
              <given-names>DJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Familial partial lipodystrophy associated with compound heterozygosity for novel mutations in the LMNA gene</article-title>
          <source>Diabetologia</source>
          <year>2004</year>
          <volume>47</volume>
          <fpage>753</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1007/s00125-004-1360-4</pub-id>
          <pub-id pub-id-type="pmid">15298354</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nabrdalik</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Strozik</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Minkina-Pedras</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jarosz-Chobot</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mlynarski</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Grzeszczak</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dunnigan-type familial partial lipodystrophy associated with the heterozygous R482W mutation in LMNA gene - case study of three women from one family</article-title>
          <source>Endokrynol Pol</source>
          <year>2013</year>
          <volume>64</volume>
          <fpage>306</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.5603/EP.2013.0010</pub-id>
          <pub-id pub-id-type="pmid">24002959</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Peshock</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Fleckenstein</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety)</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>1999</year>
          <volume>84</volume>
          <fpage>170</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">9920078</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ludtke</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Roos</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>van Hettinga</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Horst</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Worman</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>HH</given-names>
            </name>
          </person-group>
          <article-title>Post-mortem findings in Dunnigan-type familial partial lipodystrophy</article-title>
          <source>Diabet Med</source>
          <year>2010</year>
          <volume>27</volume>
          <fpage>245</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1464-5491.2009.02909.x</pub-id>
          <pub-id pub-id-type="pmid">20546275</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ludtke</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Genschel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brabant</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bauditz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Taupitz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hepatic steatosis in Dunnigan-type familial partial lipodystrophy</article-title>
          <source>Am J Gastroenterol</source>
          <year>2005</year>
          <volume>100</volume>
          <fpage>2218</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1572-0241.2005.00234.x</pub-id>
          <pub-id pub-id-type="pmid">16181372</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spuler</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kalbhenn</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Zabojszcza</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>van Landeghem</surname>
              <given-names>FK</given-names>
            </name>
            <name>
              <surname>Ludtke</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wenzel</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Muscle and nerve pathology in Dunnigan familial partial lipodystrophy</article-title>
          <source>Neurology</source>
          <year>2007</year>
          <volume>68</volume>
          <fpage>677</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="doi">10.1212/01.wnl.0000255939.73424.f8</pub-id>
          <pub-id pub-id-type="pmid">17325275</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vigouroux</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Magre</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vantyghem</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Bourut</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lascols</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Shackleton</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy</article-title>
          <source>Diabetes</source>
          <year>2000</year>
          <volume>49</volume>
          <fpage>1958</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="doi">10.2337/diabetes.49.11.1958</pub-id>
          <pub-id pub-id-type="pmid">11078466</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety)</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2000</year>
          <volume>85</volume>
          <fpage>1776</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="pmid">10843151</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vantyghem</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Vincent-Desplanques</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Defrance-Faivre</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Capeau</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fermon</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Valat</surname>
              <given-names>AS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fertility and obstetrical complications in women with LMNA-related familial partial lipodystrophy</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2008</year>
          <volume>93</volume>
          <fpage>2223</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2007-2521</pub-id>
          <pub-id pub-id-type="pmid">18364375</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mory</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Crispim</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Freire</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Salles</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Valerio</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Godoy-Matos</surname>
              <given-names>AF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phenotypic diversity in patients with lipodystrophy associated with LMNA mutations</article-title>
          <source>Eur J Endocrinol</source>
          <year>2012</year>
          <volume>167</volume>
          <fpage>423</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="doi">10.1530/EJE-12-0268</pub-id>
          <pub-id pub-id-type="pmid">22700598</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Decaudain</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vantyghem</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Guerci</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hecart</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Auclair</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Reznik</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2007</year>
          <volume>92</volume>
          <fpage>4835</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2007-0654</pub-id>
          <pub-id pub-id-type="pmid">17711925</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caldas</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Silva Junior</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Simonetti</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>EV</given-names>
            </name>
            <name>
              <surname>Farias</surname>
              <given-names>ML</given-names>
            </name>
          </person-group>
          <article-title>[Biochemical, hormonal and genetic evaluation of the families of two Brazilian patients with type 2 familial partial lipodystrophy]</article-title>
          <source>Arq Bras Endocrinol Metabol</source>
          <year>2013</year>
          <volume>57</volume>
          <fpage>583</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="doi">10.1590/S0004-27302013000800002</pub-id>
          <pub-id pub-id-type="pmid">24343626</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saha</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lessel</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hisama</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Leistritz</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Friedrich</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>GM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A novel LMNA mutation causes altered nuclear morphology and symptoms of familial partial lipodystrophy (dunnigan variety) with progeroid features</article-title>
          <source>Mol Syndromology</source>
          <year>2010</year>
          <volume>1</volume>
          <fpage>127</fpage>
          <lpage>32</lpage>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bidault</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Vatier</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Capeau</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vigouroux</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bereziat</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>LMNA-linked lipodystrophies: from altered fat distribution to cellular alterations</article-title>
          <source>Biochem Soc Trans</source>
          <year>2011</year>
          <volume>39</volume>
          <fpage>1752</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1042/BST20110675</pub-id>
          <pub-id pub-id-type="pmid">22103520</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Collet-Gaudillat</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Billon-Bancel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Beressi</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report</article-title>
          <source>Diabetes Metab</source>
          <year>2009</year>
          <volume>35</volume>
          <fpage>151</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1016/j.diabet.2009.01.001</pub-id>
          <pub-id pub-id-type="pmid">19249234</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moreau</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Boullu-Sanchis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vigouroux</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lucescu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lascols</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Sapin</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report</article-title>
          <source>Diabetes Metab</source>
          <year>2007</year>
          <volume>33</volume>
          <fpage>385</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1016/j.diabet.2007.04.005</pub-id>
          <pub-id pub-id-type="pmid">17936664</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oral</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Simha</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Ruiz</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Andewelt</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Premkumar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Snell</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Leptin-replacement therapy for lipodystrophy</article-title>
          <source>N Engl J Med</source>
          <year>2002</year>
          <volume>346</volume>
          <fpage>570</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa012437</pub-id>
          <pub-id pub-id-type="pmid">11856796</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Park</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Javor</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Cochran</surname>
              <given-names>EK</given-names>
            </name>
            <name>
              <surname>DePaoli</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Gorden</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy</article-title>
          <source>Metabolism</source>
          <year>2007</year>
          <volume>56</volume>
          <fpage>508</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="doi">10.1016/j.metabol.2006.11.010</pub-id>
          <pub-id pub-id-type="pmid">17379009</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simha</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Subramanyam</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Szczepaniak</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Quittner</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Adams-Huet</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Snell</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2012</year>
          <volume>97</volume>
          <fpage>785</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2011-2229</pub-id>
          <pub-id pub-id-type="pmid">22170723</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jazet</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Jonker</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Wijngaarden</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Lamb</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Smelt</surname>
              <given-names>AH</given-names>
            </name>
          </person-group>
          <article-title>[Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement]</article-title>
          <source>Ned Tijdschr Geneeskd</source>
          <year>2013</year>
          <volume>157</volume>
          <fpage>A5482</fpage>
          <pub-id pub-id-type="pmid">23343738</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petersen</surname>
              <given-names>KF</given-names>
            </name>
            <name>
              <surname>Oral</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Dufour</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Befroy</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ariyan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy</article-title>
          <source>J Clin Invest</source>
          <year>2002</year>
          <volume>109</volume>
          <fpage>1345</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI0215001</pub-id>
          <pub-id pub-id-type="pmid">12021250</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morrow</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Myalept approved for treatment of disorders marked by loss of body fat</article-title>
          <source>Manag Care</source>
          <year>2014</year>
          <volume>23</volume>
          <fpage>50</fpage>
          <lpage>1</lpage>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chan</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Lutz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Cochran</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Weyer</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical effects of long-term metreleptin treatment in patients with lipodystrophy</article-title>
          <source>Endocr Pract</source>
          <year>2011</year>
          <volume>17</volume>
          <fpage>922</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="doi">10.4158/EP11229.OR</pub-id>
          <pub-id pub-id-type="pmid">22068254</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Knopp</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Warth</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Charles</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Childs</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Mabuchi</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lipoprotein metabolism in pregnancy, fat transport to the fetus, and the effects of diabetes</article-title>
          <source>Biol Neonate</source>
          <year>1986</year>
          <volume>50</volume>
          <fpage>297</fpage>
          <lpage>317</lpage>
          <pub-id pub-id-type="doi">10.1159/000242614</pub-id>
          <pub-id pub-id-type="pmid">3542067</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sato</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ohkuchi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kawano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Iwanaga</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Furukawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Effect of eicosapentaenoic acid agent on aggravated hypertriglyceridemia during pregnancy</article-title>
          <source>J Obstet Gynaecol Res</source>
          <year>2013</year>
          <volume>39</volume>
          <fpage>1541</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1111/jog.12095</pub-id>
          <pub-id pub-id-type="pmid">23855742</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
